Emerging data suggest this peptide, a dual agonist targeting both GLP-1 and GIP , may represent a significant development for weight treatment. Preliminary patient tests have indicated impressive losses in visceral mass , potentially outperforming other obesity treatments. weight lose peptide Nevertheless , additional study is required to thoroughl